Ketil André Camilio

Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide

Bengt Erik Haug, Ketil André Camilio, Liv Tone Eliassen et al. · Journal of Medicinal Chemistry · 2016 · 109 citations · Full text

Class Oncolytic Peptide, Potential First, Peptide Engineering +25

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315

Ketil André Camilio, Gerd Marit Berge, Chandra Sekhar Ravuri et al. · Cancer Immunology Immunotherapy · 2014 · 81 citations · Full text

Microbial Pathogens, Immunology, Immune Regulation +25

LTX-315: A First-In-Class Oncolytic Peptide that Reprograms the Tumor Microenvironment

Baldur Sveinbj⊘rnsson, Ketil André Camilio, Bengt Erik Haug et al. · Future Medicinal Chemistry · 2017 · 80 citations · Full text

Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide

Gerd Marit Berge, Liv Tone Eliassen, Ketil André Camilio et al. · Cancer Immunology Immunotherapy · 2010 · 69 citations · Full text

Vaccination, Lymphoid Neoplasia, Therapeutic Vaccination +10

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

James Spicer, Aurélien Marabelle, Jean‐François Baurain et al. · Clinical Cancer Research · 2021 · 68 citations · Full text